Your Health, We Care
Coadministration of Alpelisib with a strong CYP3A4 inducer decreases alpelisib concentration, which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4.
Coadministration of Alpelisib with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration, which may increase the risk of toxicities. Avoid the use of BCRP inhibitors in patients treated with Alpelisib. If unable to use alternative drugs, when Alpelisib is used in combination with BCRP inhibitors, closely monitor for increased adverse reactions.
Coadministration of Alpelisib with CYP2C9 substrates (e.g., warfarin) may reduce plasma concentration of these drugs. Closely monitor when Alpelisib is used in combination with CYP2C9 substrates where decreases in the plasma concentration of CYP2C9 substrates may reduce activity of these drugs.
from FDA,2022.11
Apellix is a drug used to treat certain types of breast cancer, and its use, storage, and drug interactions require strict attention from patients and health care providers.What in···【more】
Article source：Lucius LaosRelease date：2024-12-23Recommended：82
Apellix is a therapeutic drug that targets specific types of breast cancer, and its complex pharmacological properties and strict conditions of use are critical for patients.What a···【more】
Article source：Lucius LaosRelease date：2024-12-23Recommended：97
Apellix is a drug used to treat specific types of breast cancer, and its use, storage, and daily precautions are critical for patients.Which drugs interact with AlpelisibInteractio···【more】
Article source：Lucius LaosRelease date：2024-12-23Recommended：90
Apelix is a drug for the treatment of specific diseases, and special attention should be paid to safety and effectiveness in its use.What to look out for when using AlpelisibAlpeli···【more】
Article source：Lucius LaosRelease date：2024-12-20Recommended：70
Alpelisib is the drug of choice for patients with PIK3CA-mutated breast cancer and offers new treatment hope for patients with advanced and metastatic breast cancer, especially tho···【more】
Article source：Lucius LaosRelease date：2024-08-27Recommended：143
In 2022, Alpelisib received accelerated FDA approval for patients on the PIK3CA-associated overgrowth disease spectrum, particularly those adults and children over 2 years of age w···【more】
Article source：Lucius LaosRelease date：2024-08-27Recommended：115
As the first oral small molecule drug for HR/HER2- and PIK3CA-mutated advanced breast cancer, Alpelisib effectively prolongs the progression-free survival of patients by inhibiting···【more】
Article source：Lucius LaosRelease date：2024-08-27Recommended：128
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
